Amifampridine

Product Information

Molecular Formula:
C5H7N3
Molecular Weight:
109.13
Description
Amifampridine is a drug, predominantly in the treatment of a number of rare muscle diseases. It is used to treat many of the congenital myasthenic syndromes, particularly those with defects in choline acetyltransferase, downstream kinase 7, and those where any kind of defect causes "fast channel" behaviour of the acetylcholine receptor.
Synonyms
pyridine-3,4-diamine
IUPAC Name
pyridine-3,4-diamine
Canonical SMILES
C1=CN=CC(=C1N)N
InChI
InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
InChI Key
OYTKINVCDFNREN-UHFFFAOYSA-N
Boiling Point
369.3 ℃ at 760 mmHg
Purity
> 98 %
Density
1.251 g/cm3
Solubility
12.2 [ug/mL] (The mean of the results at pH 7.4)
Application
Neuromuscular Agents
LogP
1.40840

Safety Information

Hazards
H300+H330-H311-H315-H319-H335
Precautionary Statement
P260, P261, P264, P270, P271, P280, P284, P301+P310, P302+P352, P304+P340, P305+P351+P338, P310, P312, P320, P321, P322, P330, P332+P313, P337+P313, P361, P362, P363, P403+P233, P405, and P501
Safety Class
6.1
GHS Pictogram
GHS06
Signal Word
Danger

Computed Properties

XLogP3
-0.5
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
0
Exact Mass
109.063997236
Monoisotopic Mass
109.063997236
Topological Polar Surface Area
64.9
Heavy Atom Count
8
Formal Charge
0
Complexity
74.1
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes

Patents

Publication Number Title Priority Date
CN-115260442-A A kind of fast self-healing thermoplastic polyurethane elastomer material and preparation method thereof 2022-08-28
CN-115287065-A A kind of preparation method and application of nitrogen and phosphorus co-doped carbon dots 2022-08-09
CN-115184486-A A kind of method for detecting diaminopyridine phosphate related substances by high performance liquid chromatography 2022-06-27
CN-114712321-A Diaminopyridine phosphate sustained-release tablet and preparation method thereof 2022-04-22
CN-114682104-A A kind of perovskite type conductive ceramic film and its preparation method and application 2022-03-30
CN-114517051-A Aqueous polyurethane-urea dispersion, preparation method and application thereof 2022-03-02
CN-114426981-A African swine fever virus antigen protein recombinant expression vector, recombinant plant lactic acid bacteria and preparation method and application thereof 2022-02-21
CN-114426981-B African swine fever virus antigen protein recombinant expression vector, recombinant plant lactic acid bacteria and its preparation method and application 2022-02-21
CN-114371158-A Preparation method of hydrogel kit for monitoring degradation of organophosphorus pesticide 2022-01-29
CN-114349758-A Compound with pyridine imidazole as parent nucleus and preparation method and application thereof 2022-01-21

Literatures

PMID Publication Date Title Journal
28641995 2017-07-01 Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function Clinical therapeutics
26852139 2016-05-01 Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS Muscle & nerve
26101174 2015-07-01 Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults Clinical therapeutics
25015919 2014-08-15 Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist The Journal of physiology
22922120 2012-12-06 Ectopic uterine tissue as a chronic pain generator Neuroscience
22841859 2012-11-01 Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations Neurochemistry international
22742743 2012-07-13 Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates American journal of human genetics
22805230 2012-07-01 The use of aminopyridines in neurological disorders Clinical neuropharmacology
22497693 2012-05-01 The safety profile of dalfampridine extended release in multiple sclerosis clinical trials Clinical therapeutics
22409941 2012-04-01 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis Journal of neuroimmunology
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Online Inquiry
  • Verification code
USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Copyright © 2024 BOC Sciences. All rights reserved.
Inquiry Basket